A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication

NCT ID: NCT00879736

Last Updated: 2011-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

322 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being carried out to see if patients make the lifestyle changes or take their medication as instructed by their doctor during their visit as a result of the T.H.T. patient-education training. Proper information exchange between doctors and patients is an important part of quality health care. Although many patients would like more information, they often do not ask for it directly during doctor-patient visits. The patient-training in this study specifically aims at improving patient participation during medical appointments by building communication skills such as requests for information and sharing health concerns with the doctor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Doctor-patient Communication Improvement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

THT PACE eLearning module

The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit

Group Type ACTIVE_COMPARATOR

THT PACE Training

Intervention Type BEHAVIORAL

Patient training

THT PACE eLearning module & nurse-led workshop training

THT PACE eLearning and then nurse-led workshop for training on PACE methodology

Group Type ACTIVE_COMPARATOR

THT PACE Training

Intervention Type BEHAVIORAL

Patient training

Usual care

Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

THT PACE Training

Patient training

Intervention Type BEHAVIORAL

THT PACE Training

Patient training

Intervention Type BEHAVIORAL

placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged 40 years of age or greater
* Clinical documentation of diagnosis not to target of at least one of the following: Type II Diabetes Mellitus, Hypertension or Hypercholesterolemia
* Receive a prescribed medication for the chronic disease for which they were included in the study

Exclusion Criteria

* Patients in active phase of cancer treatment (i.e. chemotherapy or radiotherapy at time of study).
* Inability to carry out the encounter with their physician in English without need of assistance
* Uncomfortable using a computer for routine activities such as regular access to the web and e-mail.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Marie-Therese Lussier

UNKNOWN

Sponsor Role collaborator

Dr. Claude Richard

UNKNOWN

Sponsor Role collaborator

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Astrazeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Marie-Thérèse Lussier, MD, BSc., MSc., FCMFC

Role: PRINCIPAL_INVESTIGATOR

Université de Montréal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Burlington, Ontario, Canada

Site Status

Research Site

Hamilton, Ontario, Canada

Site Status

Research Site

Kitchener-Waterloo, Ontario, Canada

Site Status

Research Site

Mississauga, Ontario, Canada

Site Status

Research Site

Oakville, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

THT in practice

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.